CJC NO DAC 5MG / IPAMORELIN 5MG

CJC NO DAC 5MG / IPAMORELIN 5MG

$100.00

CJC-1295 stimulates the natural release of growth hormone by activating the growth hormone-releasing hormone receptor. Ipamorelin is known for its selective action as a growth hormone secretagogue, enhancing bone health, muscle repair, and gastrointestinal function. Together, these peptides may exhibit synergistic effects, amplifying their individual benefits

Available on backorder

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

CJC-1295 (No DAC) and Ipamorelin blend is a combination of two synthetic peptides that work synergistically to stimulate growth hormone (GH) release. CJC-1295 (No DAC) is a modified form of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release GH. Ipamorelin is a selective growth hormone secretagogue and ghrelin mimetic that also promotes GH release. When combined, these peptides are believed to offer enhanced benefits compared to their individual use, particularly in areas of muscle growth, fat loss, and overall rejuvenation.

Sequence:Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Ipamorelin Sequence:Aib-His-D-2-Nal-D-Phe-Lys-NH2

  1. Growth Hormone Stimulation: Studies have shown that the combination of CJC-1295 and Ipamorelin can increase growth hormone levels by 200-1000%, with elevated GH production continuing for up to 6 days.
  2. Synergistic Effects: The combination is believed to be more effective than either peptide alone, with research suggesting a 3-5 fold increase in growth hormone release over Ipamorelin alone.
  3. Muscle Growth and Recovery: The peptide blend has demonstrated potential in enhancing muscle cell proliferation and hypertrophy, making it of interest in treating muscle-wasting conditions and improving athletic performance.
  4. Fat Loss: Increased GH levels resulting from this combination may promote more efficient breakdown of stored fat and improved metabolism.
  5. Sleep Quality: Some studies suggest that this peptide blend may improve sleep quality by promoting deeper and more restorative sleep patterns.

  1. Long-term Safety Studies: Extended research is needed to evaluate the long-term effects and safety profile of the CJC-1295/Ipamorelin combination, particularly for chronic use.
  2. Comparative Studies: Further research comparing this blend to other growth hormone-related therapies, including direct GH administration, is warranted to establish its relative efficacy and safety.
  3. Clinical Applications: Further clinical trials are required to determine the efficacy of NAD+ boosting strategies in treating or preventing age-related diseases.
  4. Optimal Dosing Regimens: Investigation into optimal delivery methods and dosing frequencies for different conditions could enhance the therapeutic potential of this peptide blend.
  5. Clinical Applications: More rigorous clinical trials are required to evaluate the potential therapeutic uses of the CJC-1295/Ipamorelin combination in various conditions such as growth hormone deficiency, muscle-wasting diseases, and age-related decline.
  6. Mechanism of Action: Additional studies to fully elucidate the molecular mechanisms by which this peptide blend exerts its diverse effects across different tissue types are needed.

  1. Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/16352683
  2. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/9849822/
  3. Gobburu, J.V., et al. (2011). Pharmacokinetics/pharmacodynamics of ipamorelin, a novel growth hormone secretagogue, in healthy volunteers. Journal of Clinical Pharmacology, 51(3), 311-320. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/20484613/
  4. Envizion Medical. (2024). Peptide Therapy: CJC-1295 + Ipamorelin. [Online].
    Available: https://www.envizionmedical.com/blog/peptide-therapy-cjc-1295-ipamorelin
  5. Peptide Sciences. (2024). CJC-1295, Ipamorelin 10mg (No DAC) (Peptide Blend). [Online].
    Available: https://www.peptidesciences.com/cjc-1295-ipamorelin-10mg-blend
The CJC-1295 (No DAC) and Ipamorelin blend represents a promising avenue for research in various fields, including muscle growth, fat loss, and anti-aging therapies. As with all peptide combinations, it is important to use this blend under controlled research conditions, and its potential benefits and risks require ongoing evaluation through further scientific studies.